Holistic
Antibody Design
A powerful AI platform for designing antibody
candidates for in-demand therapies.
De Novo antibody therapy platform
At Silica Corpora, we design and optimize therapeutic antibodies targeting priority diseases using our proprietary AI-based platform. Our modular system leverages AI-machine learning and data analytics to work exclusively with amino acid sequences.
_edited.jpg)
Our Modules
Inputs are amino acid sequences for therapeutic targets, and the outputs are amino acid sequences identifying novel antibodies in any kind of antibody format, or antibody mutants with improved biochemical properties.
Collaborations
.png)
.png)
.png)
.png)
.png)
.png)
.webp)
Our strategic partnerships and collaborations drive innovation and foster synergies, enabling us to achieve remarkable results and expand our impact.
Your DeNovo Therapeutics Partner
As a therapeutic development partner, Silica Corpora extracts value from data used in current and previous projects. Our platform can combine with your accumulated data to accelerate current programs, find new value in old data, and improve the quality of drug candidates.
A new standard for antibody discovery.
Go De Novo
Our platform makes the drug discovery process extremely accurate, extrapolating and narrowing sequences to find ideal candidates in record time and reducing the number of experimental candidates needed in pre-clinical trials.
Precise
Our system is capable of taking into account all set of parameters needed to create a successful candidate and modify them at the same time. This holistic approach is central to our drug discovery philosophy - the system must be considered in its entirety rather than focusing on a single property.
Synergetic
Our models are specifically designed to work with fine-tuned project-specific data. This allows our platform to find the right answer in every project using only a very small data set, meaning that large amounts of data are not necessarily required.
Efficient
Our De Novo methods do not disrupt existing in vitro workflows. Our methods can be easily adopted alongside established workflows, with no need for new equipment, expertise, or additional personnel.
Adaptive
Our Team
Silica Corpora was founded in 2022, emerging from a shared vision between Tim Ermak and Jaime Rosselló to transform drug discovery through leading-edge, generative technologies.
In 2023, the company added Anna-Catharina Krebs as its Chief Scientific Officer. Anna's extensive expertise in lab science accelerated Silica Corpora's capacity to develop its uniquely powerful platform. Driven by a pressing need, Silica Corpora's leadership is driven to confront and rewrite the narrative of escalating costs and time associated with bringing new prescription drugs to market.
Our mission is to develop advanced De Novo solutions that result in enhanced quality and more cost-effective antibody therapeutics for diseases with high unmet need.
